China's Innovent Biologics (OTCPK:IVBIY) has inked a strategic global collaboration with Japan's Takeda (NYSE:TAK) to advance ...

With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for ...

Scientists have made significant progress in developing cancer therapies that help patients across cancer types. However, they face limitations in determining the results of drug effectiveness, as ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

The Institute of Cancer Research finds that combining existing breast and blood cancer drugs could halt the growth of tumours ...

Bi-specific antibodies have gained traction in cancer drug development due to their ability to target two distinct antigens, thereby enhancing therapeutic efficacy simultaneously. They overcome ...

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...

Nicotinamide, a vitamin B3 derivative, could significantly reduce skin cancer risk. | Drug Discovery And Development ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...